Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Salmon Calcitonin and the Challenge of Life-Cycle Regulation

This article was originally published in RPM Report

Executive Summary

An advisory committee is recommending pulling the osteoporosis indication for salmon calcitonin. The product is, to put it bluntly, outdated: approved on standards FDA no longer accepts and now commericially irrelevant. But as a case study in regulating the full life cycle of a medicine, the issues that came up are not to be ignored.

Advertisement

Related Content

The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
Phase IV Proof of Efficacy: A Brilinta Idea?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS081114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel